NeoRecormon
Author: Michael Haydock
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
NeoRecormon (epoetin beta; Roche/Chugai) is an erythropoiesis-stimulating agent (ESA) administered by intravenous (IV) or subcutaneous (SC) injection, and is indicated for the treatment of anemia in chronic kidney disease (CKD). The drug consists of recombinant human erythropoietin and targets the erythropoietin receptor, initiating the same pathway as native erythropoietin and triggering increased blood production in bone marrow (EMC, 2017). NeoRecormon is comparable to Epogen (epoetin alfa; Amgen/Kyowa Hakko Kirin/Johnson & Johnson) in terms of its clinical profile, with similar safety, efficacy, and dosing.
TABLE OF CONTENTS
4 Product Profiles
4 NeoRecormon : Anemia in chronic kidney disease
LIST OF FIGURES
5 Figure 1: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country, 2015–24
LIST OF TABLES
6 Table 1: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country ($m), 2015–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Injectafer 
Sign up to the